Esperion Therapeutics, a commercial-stage biopharmaceutical company advancing cardiometabolic and rare disease therapies, announced plans to acquire Corstasis Therapeutics, a company advancing treatments for heart failure, liver disease, and kidney disease, on March 3rd, 2026. Corstasis’ portfolio includes the recently FDA-approved Enbumsyt (bumetanide nasal spray), a nasal spray diuretic approved by FDA in September 2025 as a treatment for edema associated with congestive heart failure, as well as hepatic and renal disease, including nephrotic syndrome, in adults.
According to a company press release, Costasis shareholders will receive an upfront payment of $75 million, as well as an additional $180 million in various regulatory and commercial milestones. Corstasis shareholders will also be eligible for low double-digit royalties on sales of Enbumsyt and follow-on products. The transaction is expected to close in Q2 2026.
“This acquisition represents a compelling and strategically aligned opportunity that accelerates Esperion’s momentum and advances our long-term Vision 2040. Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy. Enbumsyt’s novel intranasal delivery, established regulatory approval, and expanding clinical footprint make it a natural fit for our cardiovascular franchise,” said Sheldon Koenig, President and CEO, Esperion, in the release. “We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders – from patients and providers to employees and shareholders.”
“Enbumyst was purpose-built in partnership with the cardiology community to address a clear unmet need. Today’s acquisition validates our team’s vision and approach,” said Ben Esque, CEO, Corstasis Therapeutics, in the release. “We are excited about the future of Enbumyst in Esperion’s hands and its ability to intervene in the patient setting to treat worsening heart failure at home.”
